Feature

One-quarter of lung cancer patients alive at 5 years


 

Report highlights racial disparities

The report also highlights the racial disparities that persist in all aspects of lung cancer management – early diagnosis, surgical treatment, lack of treatment, and survival.

For example, Black Americans are 18% less likely to be diagnosed with early-stage disease and are 23% less likely to receive surgical treatment than their White counterparts. They are also 9% more likely to receive no treatment at all, and mortality from lung cancer among Black patients is 21% worse than it is for White patients.

The same trend is seen among Latinx persons, although they are just as likely as White patients to undergo surgical treatment.

First and foremost, “we have to make sure that the [Black and Latinx persons] are screened in an equal fashion,” Dr. McKee said. Providing screening for communities of color is one strategy that might improve screening rates, she suggested.

So, too, can outreach programs in which lung cancer experts work with leaders within these communities, because people are more likely to listen to their leaders regarding the importance of screening for early detection of lung cancer.

Physicians also need to emphasize that even for people who quit smoking decades ago, once those persons are in their 70s, “there is a spike again in lung cancer diagnoses, and that is true for both Black and White patients,” Dr. McKee stressed.

“Again, this is something that many doctors are not aware of,” she emphasized.

Dr. McKee has disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Now Takeda offers rebate if lung cancer drug fails to work
MDedge Hematology and Oncology
Antibiotic and glucocorticoid use before cancer therapy could have detrimental effect on outcomes
MDedge Hematology and Oncology
In and out surgeries become the norm during pandemic
MDedge Hematology and Oncology
Dogs show potential as medical detectives in breast cancer
MDedge Hematology and Oncology
Severe COVID two times higher for cancer patients
MDedge Hematology and Oncology
SBRT on oligoprogressive lesions: Benefit in lung cancer
MDedge Hematology and Oncology
Success in closing racial survival gap in lung and breast cancer
MDedge Hematology and Oncology
Substantial declines in mortality for most cancers
MDedge Hematology and Oncology
Most oncology trainees encounter discrimination, don’t report it, survey finds
MDedge Hematology and Oncology
EU panel endorses first-of-its-kind lung cancer drug
MDedge Hematology and Oncology